SCHEMBL4769210

SCHEMBL4769210

CCCCC(=O)Nc1c(Cl)nc(C)c(C)c1NCCOc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RECQL P46063 2/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
RAB9A P51151 2/20 0.42
TSHR P16473 2/20 0.42
NPC1 O15118 1/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767732 0.75 HTR7 (0.43) ALDH1A1RAB9ANPC1
SCHEMBL4775893 0.72 MAPT (0.48) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL4773504 0.69 MAPT (0.45) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL6722290 0.69 TOP2A (0.52) ALDH1A1GAAL3MBTL1RAB9ATSHR
SCHEMBL20801390 0.67 TLR7 (0.51) ALDH1A1GAARAB9ANPC1MEN1
SCHEMBL21632144 0.67 GAA (0.47) ALDH1A1GAARAB9ATSHRHPGD
SCHEMBL22452205 0.65 POLB (0.46) ALDH1A1GAASMN1; SMN2RAB9ATSHR
SCHEMBL4772034 0.65 HTR7 (0.42) ALDH1A1RAB9ANPC1
SCHEMBL4634361 0.64 RECQL (0.69) LMNASMN1; SMN2RECQLL3MBTL1RAB9A
SCHEMBL24808190 0.63 KDM4E (0.52) LMNAALDH1A1GAASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513524-A4 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2008-09-03 EP disclosed
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
EP-1513524-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2005-03-16 EP disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed
WO-2003103584-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 THRB 1625/4885LMNA 4400/4885ALDH1A1 1803/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP THRB 1331/4885LMNA 4818/4885ALDH1A1 940/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 THRB 1625/4885LMNA 4400/4885ALDH1A1 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.